Houlihan Lokey Advises Varsity Health Care Partners

Transaction: Houlihan Lokey Advises Varsity Health Care Partners

Houlihan Lokey is pleased to announce that Varsity Healthcare Partners (VHP), a leading healthcare services private equity firm, has made a strategic investment in Beghou Consulting (Beghou), a premier biopharmaceutical consulting firm employing more than 250 individuals globally across eight offices. The terms of the transaction were not disclosed.

VHP is a lower-middle-market private equity investment firm focused on partnering with founders, entrepreneurs, and management teams to build leading healthcare services companies. VHP’s tactical investment strategy emphasizes identifying and transacting with growth-seeking, provider-owned or founder-owned companies, leveraging VHP’s developed buy-and-build playbook to drive significant operational, managerial enhancement early in the life of each platform investment, followed by a well-resourced aggressive and multidimensional growth plan. VHP’s unique tactical investment playbook and strong track record are complemented by VHP’s distinct organizational culture, emphasizing highly collaborative engagement, strong professional accountability, and a commitment to excellence in work product and team performance.

Beghou specializes in helping emerging biopharma companies establish and manage commercial operations and make better sales and marketing decisions. The company’s capabilities span all aspects of commercial operations—from launch planning and sales force design to master data management and omnichannel analytics.

Beghou complements its consulting expertise with a suite of proprietary technology. Pharmaceutical commercial teams deploy the company’s technology platforms, including Mainsail and ARMADA, to improve sales reporting, manage customer and commercial data, forecast performance, and uncover insights on their commercial efforts.

Houlihan Lokey served as the exclusive financial advisor to VHP. This deal highlights Houlihan Lokey’s leading experience in the pharma services space and represents the firm’s 21st transaction in this sector since 2019.

View All Transactions